Acetylcysteine (N-acetylcysteine)
别名: N-acetylcysteine
中文名称:乙酰半胱氨酸
目录号:S1623 Purity: 99.97%
Acetylcysteine (N-acetyl-l-cysteine, NAC,N-acetylcysteine)是ROS抑制剂,拮抗多种蛋白酶体抑制剂的活性。它还是肿瘤坏死因子TNF的抑制剂,主要用作祛痰剂,可通过维持或恢复肝脏中谷胱甘肽的浓度来处理扑热息痛(对乙酰氨基酚过量)。Acetylcysteine(N-acetyl-l-cysteine) 通过抑制IκB kinases抑制TNF诱导的NF-κB活化。Acetylcysteine(N-acetyl-l-cysteine) 通过线粒体依赖性途径诱导凋亡并抑制铁死亡和病毒复制。在溶液中不稳定,请现配现用!
CAS: 616-91-1
客户使用Selleck的Acetylcysteine (N-acetylcysteine)发表文献207篇
- Mol Cancer, 2024 23(1):240
- Immunity, 2022 55(7):1185-1199.e8
- Mil Med Res, 2022 9(1):25
- Nat Immunol, 2020 21(7):727-735
- Cell, 2018 175(2):442-457
- Nat Commun, 2024 15(1):4124
- J Clin Invest, 2024 135(1)e179874
- Dev Cell, 2024 S1534-5807(24)00326-5
- EMBO J, 2024 10.1038/s44318-024-00217-y
- Redox Biol, 2024 76:103349
- Redox Biol, 2024 75:103292
- J Exp Clin Cancer Res, 2024 43(1):248
- EMBO Mol Med, 2024 10.1038/s44321-024-00068-4
- MedComm (2020), 2024 5(5):e562
- Int J Biol Sci, 2024 20(5):1707-1728
- Int J Biol Sci, 2024 20(6):2323-2338
- Cell Death Dis, 2024 15(11):793
- Environ Pollut, 2024 345:123467
- J Transl Med, 2024 22(1):497
- Antioxidants (Basel), 2024 13(4)430
- Cell Death Discov, 2024 10(1):122
- Mol Med, 2024 30(1):111
- Int Immunopharmacol, 2024 139:112637
- Inflammation, 2024 10.1007/s10753-024-02068-5
- Front Mol Neurosci, 2024 17:1345536
- Cell Signal, 2024 114:111004
- Drug Des Devel Ther, 2024 18:4779-4797
- J Inflamm Res, 2024 17:2245-2256
- Poult Sci, 2024 104(1):104558
- Clin Transl Sci, 2024 17(8):e13910
- Biochem Biophys Res Commun, 2024 740:151015
- Ren Fail, 2024 46(1):2354444
- BMC Cardiovasc Disord, 2024 24(1):431
- Korean J Physiol Pharmacol, 2024 28(1):21-30
- Sci Adv, 2024 10(3):eadi2012
- J Transl Int Med, 2024 12(4):437-451
- bioRxiv, 2024 2024.03.27.587011
- Nat Commun, 2023 14(1):5913
- Acta Pharm Sin B, 2023 13(8):3352-3364
- Research (Wash D C), 2023 6:0252
- Adv Healthc Mater, 2023 12(19):e2202422
- MedComm (2020), 2023 4(5):e352
- Pharmacol Res, 2023 189:106697
- Int J Biol Sci, 2023 19(8):2613-2629
- Int J Biol Sci, 2023 19(1):34-49
- Cell Commun Signal, 2023 10.1186/s12964-023-01359-y
- Inflamm Regen, 2023 43(1):22
- J Transl Med, 2023 21(1):606
- Cell Death Discov, 2023 9(1):424
- Cell Death Discov, 2023 9(1):457
- mBio, 2023 e0027223.
- Life Sci, 2023 329:121972
- Kidney Int Rep, 2023 8(9):1852-1863
- iScience, 2023 26(4):106523
- Int J Mol Sci, 2023 24(2)1667
- Int J Mol Sci, 2023 24(6)5741
- Int J Mol Sci, 2023 24(22)16474
- Int J Mol Sci, 2023 10.3390/ijms241814369
- Int J Mol Sci, 2023 24(11)9640
- Am J Physiol Cell Physiol, 2023 324(6):C1320-C1331
- Biomolecules, 2023 13(10)1464
- Int J Mol Med, 2023 52(1)61
- Am J Cancer Res, 2023 13(2):436-451
- Chin Med, 2023 18(1):68
- J Biol Chem, 2023 299(6):104710
- Pharmaceuticals (Basel), 2023 16(6)885
- Oncol Rep, 2023 49(1)16
- Oncol Rep, 2023 50(3)170
- Redox Rep, 2023 28(1):2152607
- BMC Pharmacol Toxicol, 2023 24(1):56
- Biotechnol Appl Biochem, 2023 10.1002/bab.2518
- J Orthop Surg Res, 2023 18(1):131
- bioRxiv, 2023 2023.06.13.544782
- bioRxiv, 2023 10.1101/2023.06.05.543810
- J Ginseng Res, 2023 47(1):144-154
- Acta Pharm Sin B, 2022 12(1):210-227
- Redox Biol, 2022 56:102452
- J Exp Clin Cancer Res, 2022 41(1):41
- EMBO Mol Med, 2022 14(2):e14903
- Environ Sci Technol, 2022 10.1021/acs.est.2c00585
- J Nanobiotechnology, 2022 20(1):78
- BMC Med, 2022 20(1):475
- Int J Biol Sci, 2022 18(9):3747-3761
- Cell Death Dis, 2022 13(11):1000
- Cell Death Dis, 2022 13(2):150
- Cell Death Dis, 2022 13(3):281
- Cell Mol Biol Lett, 2022 27(1):81
- JCI Insight, 2022 7(3)e145475
- Oncogene, 2022 10.1038/s41388-022-02328-4
- Free Radic Biol Med, 2022 S0891-5849(22)00222-2
- Free Radic Biol Med, 2022 190:234-246
- Free Radic Biol Med, 2022 180:220-235
- Oxid Med Cell Longev, 2022 2022:8033353
- Oxid Med Cell Longev, 2022 2022:9982449
- Front Immunol, 2022 13:827004
- Cell Biol Toxicol, 2022 10.1007/s10565-022-09756-8
- Drug Deliv, 2022 29(1):1698-1711
- Int J Mol Sci, 2022 23(15)8282
- Int J Mol Sci, 2022 23(23)14739
- Front Pharmacol, 2022 13:823975
- Int Immunopharmacol, 2022 111:108855
- Int Immunopharmacol, 2022 108:108885
- Front Pharmacol, 2022 13:1038802
- Biomolecules, 2022 12(9)1236
- Biol Direct, 2022 17(1):25
- J Ethnopharmacol, 2022 305:116069
- Mol Neurobiol, 2022 10.1007/s12035-022-02919-y
- Chem Biol Interact, 2022 369:110262
- J Gerontol A Biol Sci Med Sci, 2022 77-8:1485-1493
- Transl Oncol, 2022 19:101388
- Front Oncol, 2022 12:905230
- Viruses, 2022 14(8)1782
- Toxicology, 2022 476:153244
- Invest Ophthalmol Vis Sci, 2022 63(13):2
- Arch Biochem Biophys, 2022 731:109432
- J Inorg Biochem, 2022 230:111749
- Exp Cell Res, 2022 421(1):113362
- J Clin Transl Hepatol, 2022 10(1):42-52
- Free Radic Res, 2022 1-13
- Hematol Oncol, 2022 10.1002/hon.3007
- Curr Issues Mol Biol, 2022 44(6):2759-2771
- Neoplasma, 2022 69(6):1338-1348
- Thorac Cancer, 2022 13(17):2421-2428
- Exp Ther Med, 2022 24(1):456
- FEBS Open Bio, 2022 10.1002/2211-5463.13523
- Comput Math Methods Med, 2022 2022:8509626
- J Clin Invest, 2021 e152067
- Autophagy, 2021 1-19
- Redox Biol, 2021 S2213-2317(21)00076-8
- J Exp Clin Cancer Res, 2021 40(1):121
- EMBO Mol Med, 2021 13(9):e13193
- Cancer Lett, 2021 502:9-24
- Cell Death Dis, 2021 12(7):655
- Elife, 2021 10e69795
- Br J Pharmacol, 2021 178(5):1182-1199
- Int J Radiat Oncol Biol Phys, 2021 S0360-3016(21)00203-0
- Cell Death Discov, 2021 7(1):375
- Mol Oncol, 2021 10.1002/1878-0261.12936
- Nutr Diabetes, 2021 11(1):33
- Biochem Pharmacol, 2021 195:114863
- Cancer Sci, 2021 112(9):3455-3468
- J Nutr Biochem, 2021 S0955-2863(21)00303-X
- Front Cell Dev Biol, 2021 9:632779
- Am J Cancer Res, 2021 11(3):691-711
- Transl Oncol, 2021 14(9):101159
- Front Psychiatry, 2021 12:644383
- Food Chem Toxicol, 2021 S0278-6915(21)00805-X
- Mol Cell Biochem, 2021 10.1007/s11010-021-04197-z
- Pigment Cell Melanoma Res, 2021 10.1111/pcmr.13021
- Food Chem Toxicol, 2021 157:112550
- Arch Biochem Biophys, 2021 708:108964
- Front Genet, 2021 12:774400
- Biochem Biophys Res Commun, 2021 536:100-106
- Evid Based Complement Alternat Med, 2021 2021:8257495
- Evid Based Complement Alternat Med, 2021 2021:1821220
- J Thorac Dis, 2021 13(4):2475-2485
- Cancer Commun (Lond), 2020 10.1002/cac2.12080
- J Hazard Mater, 2020 5;391:122203
- Cell Death Differ, 2020 10.1038/s41418-020-0496-1
- ACS Appl Mater Interfaces, 2020 12(43):48296-48309
- Cell Death Dis, 2020 11(10):847
- Cell Death Dis, 2020 11(8):708
- Cell Death Dis, 2020 11(8):611
- Stem Cell Res Ther, 2020 11(1):442
- Oxid Med Cell Longev, 2020 2020:2015920
- Oxid Med Cell Longev, 2020 13;2020:3145182
- Oxid Med Cell Longev, 2020 2020:1782659
- Br J Pharmacol, 2020 10.1111/bph.15306
- J Agric Food Chem, 2020 68(40):11229-11241
- J Cell Physiol, 2020 10.1002/jcp.30172
- J Ethnopharmacol, 2020 S0378-8741(20)33579-0
- Cell Cycle, 2020 19(15):1884-1898
- Mol Cell Biochem, 2020 10.1007/s11010-020-03917-1
- Int J Biochem Cell Biol, 2020 S1357-2725(20)30219-3
- Biomed Res Int, 2020 2020:5875074
- Parasit Vectors, 2020 13(1):449
- Parasites & Vectors, 2020 449-2020)
- DNA Cell Biol, 2020 10.1089/dna.2019.5086
- Oncol Lett, 2020 19(1):291-300
- Curr Mol Med, 2020 20(4):307-317
- Redox Biol, 2019 22:101116
- Redox Biol, 2019 22:101157
- J Exp Clin Cancer Res, 2019 38(1):184
- Cell Syst, 2019 8(2):97-108
- Cell Mol Life Sci, 2019 doi: 10
- Phytomedicine, 2019 53:124-133
- Phytomedicine, 2019 52:206-215
- Oxid Med Cell Longev, 2019 2019:6595189
- Life Sci, 2019 10.1016/j.lfs.2019.116662
- Aging (Albany NY), 2019 11(22):10513-10531
- Front Oncol, 2019
- Sci Rep, 2019 9(1):18409
- Naunyn Schmiedebergs Arch Pharmacol, 2019 10.1007/s00210-019-01746-8
- J Appl Toxicol, 2019 39(8):1096-1107
- Biochem Biophys Res Commun, 2019 516(4):1265-1271
- Neoplasma, 2019 66(5):776-784
- Integr Cancer Ther, 2019 18:1534735418822120
- Int J Clin Exp Pathol, 2019 12(6):2034-2045
- Oncol Lett, 2018 16(5):6742-6748
- Acta Pharmacol Sin, 2017 38(4):488-497
- Biochem Pharmacol, 2017 146:224-232
- Oncotarget, 2017
- Cell Death Dis, 2016 7(10):e2432
- Age (Dordr), 2016 38(3):62
- Tumour Biol, 2016 37(1):1025-33
- J Cell Physiol, 2015 230(9):2281-98
- Cancer Biol Ther, 2014 15(12):1646-57
化学信息&溶解度
分子量 | 163.19 |
分子式 | C5H9NO3S |
CAS号 | 616-91-1 |
Smiles | CC(=O)NC(CS)C(=O)O |
储存条件(自收到货起) | 3年-20°C 粉状 |
此产品性质不稳定,需现配现用!建议您购买分装规格,或者在收到货后进行分装。 |
体外溶解度 | 批次: |
DMSO : 32 mg/mL ( 196.09 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 32 mg/mL Ethanol : 32 mg/mL DMSO : 33 mg/mL ( 202.21 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 33 mg/mL Ethanol : 33 mg/mL DMSO : 33 mg/mL ( 202.21 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 33 mg/mL Ethanol : 33 mg/mL Water : 98 mg/mL (超声助溶) DMSO : 33 mg/mL ( 202.21 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 33 mg/mL DMSO : 33 mg/mL ( 202.21 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : 33 mg/mL Ethanol : 33 mg/mL |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:1.67mg/ml
(10.23mM)
操作示例:以 1 mL 工作液为例,取50μL33.3mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。